ABVX

73.2009.24%
IM

Ian McGowan

Chairman of Scientific Advisory Board

Prof. Ian McGowan, M.D., Ph.D., FRCP, served as Chief Medical Officer at Orion Biotechnology Canada Ltd since March 2019 to 2025. Prof. McGowan served as Chief Scientific Officer of Orion Biotechnology Canada Ltd, until March 2019. Prof. McGowan serves as Chair of Scientific Advisory Board at ABIVAX Société Anonyme since June 25, 2018. Prof. McGowan is a Professor of Medicine in the division of Gastroenterology, Hepatology and Nutrition at University of Pittsburgh School of Medicine, Pittsburgh, PA, USA for the last 11 years where his translational research program has focused on the development of novel products for HIV prevention, the mucosal pathogenesis of HIV infection and the evaluation of products for the treatment of inflammatory bowel disease. Within the biopharmaceutical industry, he was a Senior Research Physician at GlaxoSmithKline in the UK where he contributed to the development of the antiviral drugs Amprenavir® and Abacavir®. As Director of Clinical Research at Gilead Sciences Inc. in San Francisco, he lead the team that developed tenofovir disoproxil fumarate (Viread®) for the treatment of HIV infection. He is Chief Medical Officer at AELIX Therapeutics, a Spanish biotechnology company focused on the development of a therapeutic HIV vaccine and is also Chief Scientific Officer of Orion Biotechnology, a Canadian biotechnology company developing CCR5 antagonists for HIV prevention, oncology and neuroinflammation. Prof. McGowan trained in Medicine at the University of Liverpool in the United Kingdom. He obtained his PhD in mucosal immunology from the University of Oxford and a second doctoral degree in drug development from the Liverpool School of Tropical Medicine.

Positions